Skip to content
A5218Assembly2023-2024 Session

Notify on Psych Med Changes

Official title

“Relates to designating an individual to be notified in the case of dose or brand change for psychotropic medication”

Sponsor William A. BarclayAD-120+5 co-sponsorsAffects Health
Status
In Assembly Committee
Health
Impact
6/10
Moderate
Passage
0%

Bill progress

Step 2 of 7

In committee · Health

What's happening

This bill allows patients to designate someone to be notified, in writing, before changes to their psychotropic medications are made.

Why it matters

  1. Enhances patient and caregiver involvement. By allowing patients to designate someone to be notified before changes in psychotropic medications, the bill empowers patients and their support networks to be more actively involved in critical treatment decisions, potentially improving oversight and safety.

  2. Increases transparency and informed consent. Facilities must provide written notification—including warnings about side effects and drug interactions—and receive written consent from the designated individual before making medication changes, which strengthens informed consent and may reduce adverse drug events.

  3. Addresses risks of medication changes. Special attention is given to gradual dose reductions, requiring the designee to acknowledge understanding of specific rights and risks. This helps protect patients from complications or withdrawal effects that can occur when psychotropic medications are reduced or discontinued.

  4. Broadens the definition of psychotropic drugs. The bill explicitly covers a wide range of medications (antipsychotics, antidepressants, anxiolytics, sedatives, and hypnotics), ensuring that diverse mental health treatments are included under these new notification and consent requirements.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Patients taking psychotropic medication

    The bill would give patients the right to designate someone to be notified when a facility reduces their dose or changes their medication’s brand or form.

  • Designated individuals

    They would receive written warnings about possible side effects and drug interactions, provide written consent, and acknowledge receipt of gradual dose reduction rights when applicable.

  • Facilities administering psychotropic medication

    They would need to provide the required written notifications and obtain designated individuals’ written consent for those notifications to be effective.

  • New York State Department of Health

    The commissioner would promulgate regulations governing the patient designation and notification right.

Headline styles

Notify on Psych Med Changes

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
William A. Barclay

Assembly Member · Assembly District 120

History

  1. Referred to health
  2. Referred to health

Full text

1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

5218

2023-2024 Regular Sessions

IN ASSEMBLY

March 7, 2023

Introduced by M. of A. BARCLAY, MANKTELOW, LEMONDES, DeSTEFANO, J. M. GIGLIO, BLANKENBUSH -- read once and referred to the Committee on Health

AN ACT to amend the public health law, in relation to designating an individual to be notified in the case of dose or brand change for psychotropic medication

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subdivision 3 of section 2803-c of the public health law is amended by adding a new paragraph s to read as follows:

s. (i) Pursuant to regulations promulgated by the commissioner, every patient shall have the right to designate an individual to be notified in the event that the facility reduces the dose or changes the brand or form of the patient's psychotropic medication. Such notification shall include a warning listing possible side effects and drug interactions, including side effects upon discontinuation of such drugs. Notification shall be made in writing, and shall not be effective until receipt of the written consent of the designated individual. In the case of a gradual dose reduction, a designee shall check a box acknowledging such designee has been given a copy of the rights pertaining to gradual dose reductions.

(ii) For the purposes of this paragraph, "psychotropic medication" means a medication that is administered for the purpose of affecting brain activities associated with mental processes and behavior, including, but not limited to, anti-psychotics, anti-depressants, anxiolytics, sedatives and hypnotics.

§ 2. This act shall take effect on the one hundred eightieth day after it shall have become a law.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD04918-01-3

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.